Treatment for osteoporosis in people with ß-thalassaemia

Bhardwaj, Amit; Swe, Kye Mon Min; Sinha, Nirmal K.; Osunkwo, Ifeyinwa

doi:10.1002/14651858.cd010429

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of Zinc in patients with thalassemia was associated with an increase in total body bone mineral content but no significant change in bone mass or BMD at the hip or spine (215,225). Zinc appears to be an important nutrient for growth and development in thalassemia and zinc deficiency is widespread in this cohort (226,227).…”

Section: Others (Zinc Teriparatide Strontium Ranelate Denosumab mentioning

confidence: 77%

Bone Disease in Thalassemia: A Molecular and Clinical Overview

et al. 2016

View full text Add to dashboard Cite

Thalassemia bone disease is a common and severe complication of thalassemia-an inherited blood disorder due to mutations in the α or β hemoglobin gene. In its more severe form, severe anemia is present, and treatment with frequent red blood cell transfusion is necessary. Because the body has limited capacity to excrete iron, concomitant iron chelation is required to prevent the complications of iron overload. The effects of chronic anemia and iron overload can lead to multiple end-organ complications such as cardiomyopathy, increased risks of blood-borne diseases, and liver, pituitary, and bone disease. However, our understanding of thalassemia bone disease is incomplete and is composed of a complex piecemeal of risk factors that include genetic factors, hormonal deficiency, marrow expansion, skeletal dysmorphism, iron toxicity, chelators, and increased bone turnover. The high prevalence of bone disease in transfusion-dependent thalassemia is seen in both younger and older patients as life expectancy continues to improve. Indeed, hypogonadism and GH deficiency contribute to a failure to achieve peak bone mass in this group. The contribution of kidney dysfunction to bone disease in thalassemia is a new and significant complication. This coincides with studies confirming an increase in kidney stones and associated accelerated bone loss in the thalassemia cohort. However, multiple factors are also associated with reduced bone mineral density and include marrow expansion, iron toxicity, iron chelators, increased bone turnover, GH deficiency, and hypogonadism. Thalassemia bone disease is a composite of not only multiple hormonal deficiencies but also multiorgan diseases. This review will address the molecular mechanisms and clinical risk factors associated with thalassemia bone disease and the clinical implications for monitoring and treating this disorder.

show abstract

Section: Others (Zinc Teriparatide Strontium Ranelate Denosumab mentioning

confidence: 77%

Bone Disease in Thalassemia: A Molecular and Clinical Overview

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Osteoporosis is characterized by a reduction and deterioration of bone tissue, consequently increasing bone fragility and susceptibility to fracture (2). Women are more prone to bone-loss than elderly men following postmenopausal estrogen deficiency.…”

Section: Introductionmentioning

confidence: 99%

Effect of repaglinid on ovariectomy induced bone loss in rats: comparison with 17beta-estradiol

Ulaş¹

2017

J Turgut Ozal Med Cent

View full text Add to dashboard Cite

Aim: The aim of this study was to investigate the effect of repaglinide (RPG), anti-diabetic drug used commonly diabetic patients, on bone loss ovariectomized (OVX) rats". Material and Methods: Forty Wistar albino rats were equally divided into five groups as follows: Group 1, control, non-OVX rats; Group 2, OVX rats administered 0.1 % ethanol; Group 3, OVX rats administered subcutan 17β-estradiol (E2) at a dose of 40 µg/kg; Group 4, OVX rats administered oral RPG at a dose of 0.5 mg/kg; Group 5, OVX rats administered E2 (40 µg/kg) and RPG (0.5 mg/kg) rats. Administration of drugs started 5 days after bilateral ovariectomy and continued for 35 days. After 35 days of treatment, the animals were sacrificed and the whole femurs were dissected and were analyzed for bone mineral density (BMD) and bone mineral content (BMC) by dual-energy x-ray absorptiometry (DXA). Results: There were no significant difference between OVX and RPG groups for BMC and BMD values. Compared with the OVX groups, E2 administration of OVX groups had higher BMC but no significant difference for BMD. OVX group had significantly lower value than the control group. Conclusion: RPG administrated to OVX rats for 35 days had no beneficial effect on bone loss status in OVX rats.

show abstract

Zoledronic acid: challenges and pitfalls amid rehabilitation in primary osteoporosis and beyond

Florescu,

Sima,

Costăchescu

et al. 2024

Balneo and PRM Research Journal

View full text Add to dashboard Cite

Zoledronate (or zoledronic acid) represents a standard (guideline-based) approach in the area of anti-resorptive medication (namely, an annual 15-minute perfusion of 5 mg for os-teoporosis treatment), while the same drug (with doses/regimes variations) is used for other bone metabolic conditions such as Paget’s disease of the bone or skeleton metastasis originating from different cancers. The objective of this narrative review was to highlight the most recent published data with respect to zoledronic acid use as part of the complex clinical management amid primary osteoporosis in addition to other osteo-metabolic clin-ical entities. This was a research based on exploring PubMed database with respect to the search words “zoledronic acid” and “primary osteoporosis”. We included highly relevant (from the clinical perspective), English-published, full-length articles that have been re-cently published (between January 2023 and March 2024). From 249 results, 31 articles met the inclusion timeline criteria across the 15-month analysis and the final results were based on data provided from 16 articles. Important insights concern not only the zoledronic acid administration, the efficacy and the safety profile, but, also, an extension on daily indications with concern to diabetic bone disease, liver osteodystrophy, osteogen-esis imperfecta or Paget’s disease of the bone. Keywords: osteoporosis, rehabilitation, zoledronic acid, DXA, hypercalcemia, bone, surgery, prosthesis, Paget’s disease of the bone, liver osteodystrophy

show abstract

Treatment for osteoporosis in people with ß-thalassaemia

Cited by 4 publications

References 25 publications

Bone Disease in Thalassemia: A Molecular and Clinical Overview

Bone Disease in Thalassemia: A Molecular and Clinical Overview

Effect of repaglinid on ovariectomy induced bone loss in rats: comparison with 17beta-estradiol

Zoledronic acid: challenges and pitfalls amid rehabilitation in primary osteoporosis and beyond

Contact Info

Product

Resources

About